| Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. | |
| | |
MedLine Citation:
|
PMID: 21849011 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aims: Efficacy of antimuscarinic therapy for overactive bladder (OAB) has been demonstrated; however, the durability of its effects is unknown. The study was conducted to evaluate symptom change and retreatment rate after discontinuation of antimuscarinic therapy. Also, we tried to find risk factors for retreatment. Methods: This was a prospective, randomised, open-label, multicentre trial at four university hospitals. Women who had OAB symptoms for ≥ 6 months and who showed successful response to 1 month of Tolterodine 4 mg medication were randomly assigned to one of three groups: (A) discontinue medication, (B) 2-month additional medication and (C) 5-month additional medication. After completion of the 1-, 3- or 6-month treatment, patients stopped the medication and were followed up for additional 3 months to assess symptom relapse and retreatment rates. Risk factors for retreatment were evaluated. Results: Of a total of 558 patients who took the study medication, 173 were randomised and 108 (A: 40, B: 40, C: 28) were included in the analysis. At the end of the treatment, the mean micturition frequency was decreased to 8.3/24 h from 11.7/24 h, and the mean urgency episode was decreased to 2.2/24 h from 8.0/24 h. Three months after discontinuation, the micturition frequency and the urgency episode were increased to 9.1/24 and 4.4/24 h respectively. Sixty five per cent of patients requested retreatment, and 62% experienced symptom relapse. Baseline health-related quality of life was the only independent risk factor for retreatment. Discussion and conclusion: Discontinuation of antimuscarinic therapy resulted in high symptom relapse and retreatment rates regardless of treatment duration. The results provide new information on the durability of the efficacy of antimuscarinics, and may improve treatment efficacy by promoting the medication persistence of antimuscarinics in OAB patients. |
| | |
Authors:
|
Y-S Lee; M-S Choo; J Y Lee; S-J Oh; K-S Lee |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of clinical practice Volume: 65 ISSN: 1742-1241 ISO Abbreviation: Int. J. Clin. Pract. Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-08-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9712381 Medline TA: Int J Clin Pract Country: England |
Other Details:
|
Languages: eng Pagination: 997-1004 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Urology, Sungkyunkwan University School of Medicine, Samsung Changwon Hospital, Changwon, Korea Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effectiveness of interventions to improve antidepressant medication adherence: a systematic review.
Next Document: Dimension Reduction with Gene Expression Data Using Targeted Variable Importance Measurement.